Peptides for muscle growth: what the evidence shows

The largest family releases your own growth hormone. GHRH analogs, including sermorelin, CJC-1295 and tesamorelin, copy the brain’s releasing signal. Ghrelin mimetics, including GHRP-2, GHRP-6, hexarelin, ipamorelin and the oral small molecule MK-677, act on a second pituitary receptor, the ghrelin receptor GHS-R1a. The two routes add together, which is why the pairs sold online usually combine one of each. Because both work through the pituitary, the body’s own feedback still caps the response.

The second family skips the pituitary and supplies the growth signal directly. IGF-1 LR3 and IGF-1 DES are altered forms of IGF-1 that escape the binding proteins that normally hold IGF-1 in check, so more of it reaches cells. That makes them more potent, and it also removes a safety catch.

The third and fourth families act inside muscle. Mechano growth factor is the stretch-switched piece of the IGF-1 gene product, sold as a synthetic peptide and a pegylated form called PEG-MGF. Follistatin-344 binds myostatin and activin, releasing the brake. Both are early research, and the human data are thin or absent.^471211273035

Sermorelin is the oldest of the group. It was once an approved medicine, used to test pituitary function and to help children with growth hormone deficiency grow, and in those children height velocity rose and held through 12 months. In older adults the trials are small. Eleven men aged 64 to 76 took it nightly for six weeks, and nighttime growth hormone rose and some strength measures improved, while IGF-1 and body composition did not change. In a five-month study of a close analog, lean mass and insulin sensitivity rose in men only, and the IGF-1 rise faded over time.

CJC-1295 was built to last. It binds albumin in the blood and has a half-life of about six to eight days. In two placebo-controlled trials in healthy adults, one injection raised growth hormone 2 to 10-fold for six days or more and IGF-1 1.5 to 3-fold for up to 11 days. A second study found the natural pulses persisted, with the baseline between them lifted. No trial has measured muscle or strength.

Tesamorelin is the only one with a current FDA approval, for one narrow use. In a 26-week trial of 412 adults with HIV and excess abdominal fat, visceral fat fell 15.2 percent while it rose 5.0 percent on placebo. Its label lists joint pain, swelling and muscle pain as common side effects and warns about glucose intolerance and fluid retention, which are worth reading as the honest cost sheet for raising growth hormone in general.^45678941

IGF-1 LR3 and IGF-1 DES are the most potent compounds in this chapter and the least tested in people. Both slip past the binding proteins that normally hold most IGF-1 in reserve. DES was about 10 times more active than IGF-1 on muscle cells in a dish. In pigs and monkeys, these variants lowered blood sugar two to three times more than natural IGF-1, and for much longer. The approved, natural-sequence IGF-1 medicine shows what that means in practice. In a registry of 306 young patients, 80 had at least one low blood sugar event.

Mechano growth factor is the most contested idea here. Early cell work found its peptide raised muscle cell growth independently of the IGF-1 receptor. Later work found the effect depended on that receptor, and a replication study at two drug companies found no apparent effect on muscle cells at all. In mice given sustained gene delivery of a related E peptide, muscles grew larger and weaker.

Follistatin has the most dramatic animal data. Mice engineered to make extra follistatin in muscle gained striking mass. In people, it has been tested only as gene therapy, in six adults with Becker muscular dystrophy, where four walked farther, and in a small inclusion body myositis trial whose findings were disputed in print. When anti-doping scientists bought 17 black-market follistatin products, only 9 contained follistatin.^{262829313233343536373839}

The largest natural growth hormone pulse comes in early deep sleep. MK-677 increased the deepest stage of sleep by about half in young adults, while hexarelin given in the evening reduced it and raised cortisol. Before reaching for a growth hormone releaser, it is worth asking how well you sleep, because sleep is the body’s own releaser.

Resistance training is the other lever every study in this chapter assumes. It is what switches on the muscle’s local growth signals, and it is the only thing in this chapter shown to turn growth signals into strength. Protein supplies the material. In one short MK-677 study, dieting volunteers went from losing protein to a slight positive balance, which shows how closely this axis is tied to nutrition.

The labs follow the side effects. Growth hormone and its mimics raise blood sugar and lower insulin sensitivity, so HbA1c and fasting glucose belong on the baseline. GHRP-2 and hexarelin raise prolactin and cortisol. Testosterone is the other major anabolic hormone, and a low level is a simpler explanation for stalled progress than a missing peptide.^21182222415

The growth hormone releasers reliably raise growth hormone and IGF-1, and in older adults they add some lean mass. What they have not shown in controlled trials is the thing most people want, more strength and better function. They also carry a predictable cost in blood sugar, fluid and, for some, cortisol and prolactin. The direct growth signals are more potent and much less tested, with real concerns about blood sugar and product quality.

The best question to ask a clinician is what is actually limiting your progress. Low testosterone, poor sleep, too little protein and an unprogressive program are all common, measurable and fixable. If a growth hormone releaser still makes sense after that, a baseline of glucose, HbA1c and hormones lets you see what it changed beyond the mirror.²⁴²⁸³⁹